Tirzepatide for weight loss after kidney transplant
Official title: Safety and Efficacy of Tirzepatide (Spartina) in Obese Kidney Transplant Recipients: A Pilot Study on Weight Loss, Gastrointestinal Tolerability, and Graft Function
Run by Shahid Beheshti University of Medical Sciences · NCT07423247 · Data updated 2026-11-12
This will test whether weekly tirzepatide helps adults at least one year after a kidney transplant lose weight and improve blood sugar and kidney-related outcomes.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | Shahid Beheshti University of Medical Sciences Academic / other |
| Locations | 1 site (Tehran) |
| Status | Recruiting |
| Started | January 1, 2026 |
| Main results expected | July 2026 |
| Study ends | September 2026 |
| Registry record updated | February 20, 2026 |
| Trial ID | NCT07423247 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18 years) at least 12 months post-kidney transplant with BMI ≥27 kg/m², stable serum creatinine over the prior 3 months, and a stable immunosuppressive regimen are ideal candidates.
✕Probably not a fit
Patients with eGFR <30 mL/min/1.73m², recent acute rejection, history of pancreatitis, severe gastroparesis, or medullary thyroid carcinoma/MEN2 are excluded and unlikely to receive benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, single-arm pilot study enrolling adults at least 12 months after kidney transplantation with BMI ≥27 kg/m² and stable graft function. Participants will receive once-weekly subcutaneous tirzepatide for 24 weeks with a stepwise dose escalation and close monitoring. The protocol emphasizes safety monitoring for gastrointestinal adverse events, dehydration, and effects on immunosuppressive drug exposure and graft function. Outcomes include weight change, glycemic measures, renal function stability, and adverse events.
Why it matters
Potential benefit: If successful, tirzepatide could provide meaningful weight loss and improved metabolic control for transplant recipients while helping protect long-term graft and cardiovascular health.
How similar studies have gone: Tirzepatide has produced large weight loss and better glycemic control in non-transplant populations, but its safety and effects in kidney transplant recipients remain largely untested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Kidney transplant recipient with ≥12 months since transplantation * BMI ≥ 27 kg/m² * Stable graft function in the last 3 months (serum creatinine variation \< 20%) * Stable immunosuppressive regimen * Ability to provide written informed consent Exclusion Criteria: * History of pancreatitis * Severe gastroparesis * History of medullary thyroid carcinoma (MTC) or MEN2 syndrome * eGFR \< 30 mL/min/1.73m² * Acute rejection episode within the past 6 months * Any condition judged by the investigator to interfere with study participation or safety
Where it's running
-
Nooshin Dalili
Tehran, Iran Recruiting
Study contacts
- Principal investigator: Nooshin Dalili — Sbmu
- Study coordinator: Nooshin Dalili, MD
- Email: dr.nooshindalili@gmail.com
- Phone: 00989122404331
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Weight-loss drug stoppage and restart effects on brain, mood, and daily life
This study tests what happens to brain signals, mood, sleep, and daily functioning when a tirzepatide user pauses the medication and then restarts it.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.